G

Genfit SA
PAR:GNFT

Watchlist Manager
Genfit SA
PAR:GNFT
Watchlist
Price: 4.08 EUR 1.49% Market Closed
Market Cap: 203.4m EUR
Have any thoughts about
Genfit SA?
Write Note

Genfit SA
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genfit SA
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
G
Genfit SA
PAR:GNFT
Cash from Operating Activities
-€41.5m
CAGR 3-Years
19%
CAGR 5-Years
10%
CAGR 10-Years
-12%
Valneva SE
PAR:VLA
Cash from Operating Activities
-€142.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nanobiotix SA
PAR:NANO
Cash from Operating Activities
-€1m
CAGR 3-Years
67%
CAGR 5-Years
50%
CAGR 10-Years
18%
Inventiva SA
PAR:IVA
Cash from Operating Activities
-€84.7m
CAGR 3-Years
-25%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Cash from Operating Activities
€26.8m
CAGR 3-Years
-32%
CAGR 5-Years
68%
CAGR 10-Years
N/A
OSE Immunotherapeutics SA
PAR:OSE
Cash from Operating Activities
€58.4m
CAGR 3-Years
N/A
CAGR 5-Years
49%
CAGR 10-Years
N/A
No Stocks Found

Genfit SA
Glance View

Market Cap
203.3m EUR
Industry
Biotechnology

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

GNFT Intrinsic Value
4.97 EUR
Undervaluation 18%
Intrinsic Value
Price
G

See Also

What is Genfit SA's Cash from Operating Activities?
Cash from Operating Activities
-41.5m EUR

Based on the financial report for Jun 30, 2024, Genfit SA's Cash from Operating Activities amounts to -41.5m EUR.

What is Genfit SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-12%

Over the last year, the Cash from Operating Activities growth was 17%. The average annual Cash from Operating Activities growth rates for Genfit SA have been 19% over the past three years , 10% over the past five years , and -12% over the past ten years .

Back to Top